Modeling mitochondrial dysfunctions in the brain: From mice to men

Journal of Inherited Metabolic Disease

Volumn 35, Issue 2, 2012, Pages 193-210

  Breuer, Megan E ^a,b   Willems, Peter H G M ^a   Russel, Frans G M ^a   Koopman, Werner J H ^a   Smeitink, Jan A M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; D 264; DJ 1 PROTEIN; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LACTACYSTIN; LEVACECARNINE; LEVODOPA; LITHIUM; MECLOFENOXATE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NORTRIPTYLINE; OXIDOPAMINE; PARKIN; PRAMIPEXOLE; PRESENILIN 1; ROTENONE; SERTRALINE; TAR DNA BINDING PROTEIN; TAU PROTEIN; THIOCTIC ACID; TWINKLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; BRADYKINESIA; BRAIN DISEASE; BRAIN FUNCTION; COGNITION; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DJ 1 GENE; DRUG ABSORPTION; DRUG MECHANISM; GENE; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; KNOCKOUT MOUSE; LOW DRUG DOSE; MITOCHONDRIAL COMPLEX I DEFICIENCY; MITOCHONDRIAL RESPIRATION; MOTOR COORDINATION; MOTOR PERFORMANCE; NDUFS4 GENE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKIN GENE; PARKINSON DISEASE; PATHOGENESIS; PINK1 GENE; PS1 GENE; PSYCHOMOTOR DISORDER; REVIEW; SCHIZOPHRENIA; SOD1 GENE; SPINAL CORD DISEASE; TFAM GENE; TRANSGENIC MOUSE; TRANSGENIC RAT; YEAST ARTIFICIAL CHROMOSOME;

ANIMALS; BRAIN; BRAIN DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; SPINAL CORD DISEASES;

EID: 84863422150     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9375-8     Document Type: Review

References (100)

1. Adhihetty PJ, Beal MF (2008) Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med 10(4):275-290
2. Alam M, Mayerhofer A, Schmidt WJ (2004) The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behav Brain Res 15(1-2):117-124
3. Andres-Mateos E, Perier C, Shang L et al. (2007) DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 104:14807-14812
4. Andrews ZB, Diano S, Horvath TL (2005) Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat Rev Neurosci 6(11):829-840
5. Attems J, Ittner A, Jellinger K, Nitsch RM, Maj M, Wagner L, Gotz J, Heikenwalder M (2011) Reduced secretagogin expression in the hippocampus ofP301L tautransgenic mice. JNeural Transm 118 (5):737-745
6. Benit P, Goncalves S, Dassa EP, Briere JJ, Rustin P (2008) The variability of the harlequin mouse phenotype resembles that of human mitochondrial-complex I-deficiency syndromes. PLos One 3(9):e3208
7. Bennett MC, Mlady GW, Kwon YH, Rose GM (1996) Chronic in vivo sodium azide infusion induces selective and stable inhibition of cytochrome c oxidase. J Neurochem 66(6):2606-2611
8. Ben-Shachar D (2009) The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 116:1383-1396
9. Boveris A, Navarro A (2008) Brain mitochondrial dysfunction in aging. IUBMB Life 60(5):308-314
10. Braw Y, Malkesman O, Merlender A et al. (2006) Stress hormones and emotion-regulation in two genetic animal models of depression. Psychoneuroendocrinology 31(9):1105-1116
11. Browne SE, Bowling AC, MacGarvey U et al. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41 (5):646-653
12. Carreras MC, Franco MC, Finocchietto PVet al. (2007) The biological significance of mtNOS production. Front Biosci 12:1041-1048
13. Chen CM (2011) Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. Chang Gung Med J 34(2):135-152
14. Cheng Y, Feng Z, Zhang Q, Zhang J (2006) Beneficial effects of melatonin in experimental models of Alzheimer's disease. Acta Pharm Sinica 27(2):129-139
15. Choi WS, Kruse SE, Palmiter RD, Xia Z (2008) Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP + or paraquat Proc Natl Acad Sci 105(39):15136-15141
16. Chou AP, Li S, Fitzmaurice AG, Bronstein JM (2010) Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology 31 (4):367-372
17. Clay HB, Sillivan S, Konradi C (2010) Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci. doi:10.1016/j.ijdevneu.2010.08.007
18. Crawley JN (1999) Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835(1):18-26
19. Cryan JF, Slattery DA (2010) GABAB receptors and depression. Current status. Adv Pharmacol 58:427-451
20. Cui K, Luo X, Xu K, Ven Murthy MR (2004) Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog Neuro- psychopharmacol Biol Psych 28:771-799
21. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66(5):646-661
22. de Moura MB, dos Santos LS, Van Houten B (2010) Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 51(5):391-405
23. Dragicevic N, Mamacarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC (2010) Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimer's Dis 20(Suppl 2): S535-S550
24. Duan W, Mattson MP (1999) Dietary restriction and 2-Deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 57:195-206
25. Duan W, Guo Z, Mattson MP (2000) Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid. Exp Neurol 165 (1):1-11
26. 10 and remacemide in transgenic mouse models ofHuntington's disease. J Neurosci 22(5):1592-1599
27. Fornai F, Longone P, Cafaro L et al. (2008) Lithium delays progression of amyotrophic lateral sclerosis. PNAS 105(6):2052-2057
28. Frisar Z, Hroudova J (2010) Intracellular signaling pathways and mood disorders. Folia Biol (Praha) 56(4):135-148
29. Galter D, Pernold K, Yoshitake T et al. (2010) MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav 9(2):173-181
30. Garcia FD, Coquerel Q, Kijve E, Dechelotte P, Harro J, Fetissoy SO (2011) Autoantibodies reacting with vasopressin and oxytocin in relation to cortisol secretion in mild and moderate depression. Prog Neuropsychopharmacol Biol Psychiatry 35 (1):118-125
31. Gardner A, Boles RG (2010) Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsycho-pharmacol Biol Psychiatry. doi:10.1016/j.pnpbp.2010. 07.030
32. Gasser T (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 11:e22
33. Ghezzi D, Sevrioukova I, Invernizzi F et al. (2010) Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-induced factor. Am J Hum Genet 86(4):639-649
34. Gong Y, Chai Y, Ding JH, Sun XL, Hu G (2010) Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain. Neurosci Lett. doi:10.1016/j.neulet.2010.11.006
35. Goodall EF, Morrison KE (2006) Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 8(1 1):1-22
36. Graham BH, David Sweatt J, Craigen WJ (2002) Noninvasive, in vivo approaches to evaluating behavior and exercise physiology in mouse models ofmitochondrial disease. Methods 26(4):364-370
37. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305(5684):626-629
38. Gurney ME, Pu H, Chiu AY et al. (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264(5166):1772-1775
39. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S (2006) 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase-3 dependent activation of protein kinase Cδ*. J Biol Chem 281(9):5373-5382
40. Hirai K, Aliev G, Nunomura A et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosi 21(9):3017-3023
41. Ingraham CA, Burwell LS, Skalska J, Brookes PS, Howell RL, Sheu SS, Pinkert CA (2009) NDUFS4: creation of a mouse model mimicking a Complex I disorder. Mitochondrion 9(3):204-210
42. Ishimura R, Martin GR, Ackerman SL (2008) Loss of apoptosis-inducing factor results in cell-type-specific neurogenesis defects. J Neurosci 28(19):4938-4948
43. Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V, Cleveland DW (2010) Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 67(4):575-587
44. Janus C, D'Amelio S, Amitay O et al. (2000) Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes. Neurobiol Aging 21(4):541-549
45. Kim GW, Copin JC, Kawase M, Chen SF, Sato S, Gobbel GT, Chan PH (2000) Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitroproprionic acid. J Cereb Blood flow Metab 20 (1):119-129
46. King DL, Arendash GW (2002) Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75(5):627-642
47. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167 (11):1305-1320
48. Kruse SE, Watt WC, Marcinek DJ, Kapur RP, Schenkman KA, Palmiter RD (2008) Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy Cell Metab 7(4):312-320
49. Kulic L, Wollmer MA, Rhein V et al. (2009) Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration. Neurobiol Aging. doi:10.1016/j. neurobiolaging2009.10.014
50. Kumar A, Prakash A, Dogra S (2011) Protective effect of curcumin (Curcuma longa) against D-galactose-induced senescence in mice. J Asian Nat Prod Res 13(1):42-55
51. Kuperschmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MBH (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23:3766-3779
52. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product ofmeperidine-analog synthesis. Science 219(4587):979-980
53. Lenzken SC, Romeo V, Zolezzi F et al. (2011) Mutant SOD1 and mitochondrial damage alter expression and splicing of genes controlling neuritogenesis in models of neurodegeneration. Hum Mutat 32(2):168-182
54. Levenson CW, Rich NJ (2007) Eat less, live longer? New insights into the role of caloric restriction in the brain. Nutr Rev 65 (9):412-415
55. Levine MS, Klapstein GJ, Koppel A et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58(4):515-532
56. Levine JS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF (2004) Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trend Neurosci 27 (11):691-697
57. Li C, Biswas S, Li X, Dutta AK, Le W (2010) Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1- methyl-4-phenyl-1,2,3,6- tetrahydropyridine and lactacystin. J Neurosci Res 88:2513-2523
58. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113):787-795
59. Liu J, Atamna H, Kuratsune H, Ames BN (2002) Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann NYAcad Sci 959:133-166
60. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R (1994) Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 174(1):67-72
61. Mounsey RB, Teismann P (2010) Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinson's Dis 2011:61;7472
62. Navarro A, Boveris A (2008) Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria- targeted antioxidants. Adv Drug Deliv Rev 60(13-14):1534-1544
63. Nehru B, Verma R, Khanna P, Sharma SK (2008) Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment ofcentrophenoxine. Brain Res 1201:122-127
64. Novak MJ, Tabrizi SJ (2010) Huntington's disease. BMJ 340:c3109. doi:10.1136/bmj.c3109
65. Oliveira JM (2010) Nature and cause ofmitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J Neurochem 114(1):1-12
66. Packer L, Tritschler HJ, Wessel K (1997) Neuroprotection by the metabolic antioxidant α-lipoic acid. Free Radical Bio Med 22:359-378
67. Pan R, Qiu S, Lu DX, Dong J (2008) Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin Med J 121(9):832-839
68. Pang TYC, Du X, Zajac MS, Howard ML, Hannan AJ (2009) Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Gen 18(4):753-766
69. Patki G, Che Y, Lau YS (2009) Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease. Front Aging Neurosci 11:1-3
70. PengY, Sun J, Hon S, Nylander AN, XiaW, FengY, WantX (2010) L-3-n-Butylphthalide improves cognitive impairment and reduces amyloid-ß in a transgenic model of Alzheimer's disease. J Neurosci 30(24):8180-8189
71. Petkov VD, MosharrofAH, Petkov VV (1988) Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and ofciticholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice). Acta Physiol Pharmacol Bulg 14(1):3-13
72. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F (1994) Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 55(15): PL271-276
73. Quintana A, Kruse SE, Kapur RP, Sanz E, Palmiter RD (2010) Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc Natl Acad Sci USA 107(24):10996-11001
74. Resende R, Moreira PI, Proenca T, Deshpande A, Busciglio J, Pereira C, Oliveira CR (2008) Brain oxidative stress in a triple-transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 44:2051-2057
75. Reyes NA, Fisher JK, Austgen K, VandenBerg S, Huang EJ, Oakes SA (2010) Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model ofamyotrophic lateral sclerosis. J Clin Invest 120(10):3673-3679
76. Scaglia F (2010) The role ofmitochondrial dysfunction in psychiatric disease. Dev Disabil Res Rev 16(2):136-143
77. Schapira AH (2010) Complex I: inhibitors, inhibition and neuro-degeneration. Exp Neurol 224(2):331-335
78. Schiff M, Benit P, Coulibaly A, Loublier S, El-Khoury R, Rustin P (2011) Mitochondrial response to controlled nutrition in health and disease. Nutr Rev 69(2):65-75
79. Searcy DG (2003) Metabolic integration during the evolutionary origin of mitochondria. Cell Res 13(4):229-238
80. Seo JS, Leem YH, Lee KW, Kim SW, Lee JK, Han PL (2010) Severe motor neuron degeneration in the spinal cord of the TG2576 mouse model ofAlzheimerdisease. JAlzheimers Dis 21(1):263-276
81. Shan X, Chiang PM, Prince DL, Wong PC (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci USA 107 (37):16325-16330
82. Smeitink J, van den Heuvel L, DiMauro S (2001) The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 2 (5):342-352
83. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggler B, Hardeland R (2006) Melatonin in Alzheimer's disease and other neurode-generative disorders. Behav Brain Function 2:15-37
84. Strazielle C, Jazi R, Verdier Y, Qian S, Lalonde R (2009) Regional brain metabolism with cytochrome c oxidase histochemistry in a rø-//A246E mouse model of autosomal dominant Alzheimer's disease: correlations with behavior and oxidative stress. Neurochem Int 55:806-814
85. Tang TS, Chen X, Liu J, Bezprozyanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 27(30):7899-7910
86. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510-518
87. Tyynismaa H, Mjosund KP, Wanrooij S et al. (2005) Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci 102(49):17687-17692
88. Vali S, Mythri RB, Jagatha B et al. (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 149(4):917-930
89. Van Raamsdonk JM, Warby SC, Hayden MR (2007) Selective degeneration in YAC mouse models of Huntington disease. Brain Res Bull 72(2-3):124-131
90. Virmani MA, Biselli R, Spadoni A et al. (1995) Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res 32 (6):383-389
91. Wang LH, Qin ZH (2006) Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies. Acta Pharmacol Sin 27(10):1287-1302
92. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA (2005) Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93:953-962
93. Wang H, Guan Y, Wang X et al. (2007) Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur J Neurosci 26 (3):633-641
94. Weeber EJ, Levy M, Sampson MJ et al. (2002) The role ofmitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem 277(21):18891-18897
95. Weinstock M, Shoham S (2003) Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J Neural Transm 111(3):347-366
96. Wu CL, Hwang CS, Chen SD, Yin JH, Yang DI (2010) Neuro-protective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity; therapeutic implications for Huntington's disease. Ann N Y Acad Sci 1201:8-12
97. Xiong N, Huang J, Zhang Z et al. (2009) Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One 4(11):e7878
98. Xu YF, Gendron TF, Zhang YJ et al. (2010) Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggre-gation, motor deficits, and early mortality in transgenic mice. J Neurosci 30(32):10851-10859
99. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrente RJ, Beal MF (2009) Combination therapy with conenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 109 (5):1427-1439
100. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. JNeurochem 105:1970-1978